GC Biopharma Corp
Clinical trials sponsored by GC Biopharma Corp, explained in plain language.
A biopharmaceutical company developing plasma-derived and recombinant therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new vaccine shield against COVID-19? a trial aims to find out Results expected May 2027 (estimated)
- Can a direct brain infusion slow sanfilippo syndrome? Results expected Jun 2027 (estimated)
- New chickenpox vaccine shows promise in large Kids' trial Results expected Aug 2027 (estimated)
-
Hunterase extended trial shows promise for managing hunter syndrome
Disease control CompletedThis study looked at the long-term safety and effectiveness of Hunterase (idursulfase beta) in 30 people with Hunter syndrome over about one year. Participants had either completed a previous phase 3 study or had used Hunterase for at least six months. The goal was to monitor sid…
Phase 3 • Sponsor: GC Biopharma Corp • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hemophilia shot shows early promise in small safety trial
Disease control CompletedThis early-phase study tested a new drug called MG1113, given as a shot under the skin, in 15 adults with severe hemophilia A or B. The main goal was to check safety and how the drug moves through the body. Participants received multiple doses to see if the drug is well-tolerated…
Phase 1 • Sponsor: GC Biopharma Corp • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC